CareDx (NASDAQ:CDNA) Releases Earnings Results, Misses Estimates By $0.12 EPS

CareDx (NASDAQ:CDNA) announced its quarterly earnings data on Tuesday. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.12), FiscalAI reports. The firm had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $102.76 million. CareDx had a net margin of 19.65% and a return on equity of 20.15%. The business’s quarterly revenue was up 25.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.18 EPS.

Here are the key takeaways from CareDx’s conference call:

• Q4 revenue of $108.4 million (+25% y/y) and full‑year revenue of $379.8 million (+14% y/y), testing volume up 17% in Q4, ~69% non‑GAAP gross margin, positive adjusted EBITDA (Q4 $6.5M, FY $31.7M), roughly $201M cash and no debt, and ~$88M of share repurchases in 2025.
• Management highlighted multiple product launches and pipeline progress, including AlloSure Heart (pediatrics), AlloSure Plus, HistoMap Kidney and pivotal AlloHeme (ACROBAT) data that detected relapse a median 41 days earlier with 85% sensitivity/92% specificity and a planned commercial rollout in early 2027 targeting payer coverage in 2028.
• A draft Medicare Local Coverage Determination (LCD) could reduce annual revenue by about $15M; the company baked a conservative $7.5M (half‑year) hit into 2026 guidance and also expects a PLA code reimbursement cut that pushes blended revenue per test into the low $1,400s.
• Operations and cash collection improved materially—DSO improved from 71 to 41 days and 2025 cash collections rose ~32% to $405.6M—and the company is investing ~$10M in Epic Aura/Epic Enterprise LIMS integrations, which management says is already reducing login issues (~40%) and should improve order quality, billing and long‑term volume growth.

CareDx Stock Up 2.4%

Shares of NASDAQ CDNA traded up $0.46 on Tuesday, hitting $19.25. The company had a trading volume of 583,131 shares, compared to its average volume of 714,990. CareDx has a 12-month low of $10.96 and a 12-month high of $22.95. The firm has a market capitalization of $990.09 million, a P/E ratio of 16.18 and a beta of 2.51. The business has a 50 day moving average of $19.68 and a two-hundred day moving average of $16.74.

Analysts Set New Price Targets

A number of research analysts have weighed in on CDNA shares. Craig Hallum lowered CareDx from a “buy” rating to a “hold” rating and set a $26.00 price target on the stock. in a research note on Tuesday, January 6th. Wells Fargo & Company upped their target price on CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CareDx in a research report on Monday, December 29th. Wall Street Zen cut CareDx from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, BTIG Research upped their price objective on shares of CareDx from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, CareDx presently has an average rating of “Hold” and an average target price of $26.67.

Insider Transactions at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total transaction of $407,964.80. Following the sale, the chief executive officer owned 597,405 shares in the company, valued at $12,641,089.80. This trade represents a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 29,636 shares of company stock valued at $625,949 over the last three months. 4.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On CareDx

Large investors have recently added to or reduced their stakes in the company. Quarry LP purchased a new position in CareDx in the 4th quarter valued at about $25,000. Meeder Asset Management Inc. acquired a new position in shares of CareDx in the fourth quarter worth about $79,000. Quantbot Technologies LP purchased a new position in CareDx in the third quarter valued at about $89,000. Tower Research Capital LLC TRC grew its stake in CareDx by 120.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after purchasing an additional 4,160 shares in the last quarter. Finally, State of Wyoming acquired a new stake in CareDx during the 4th quarter valued at approximately $155,000.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.